Chemotherapy: Open Access
Open Access

Abstract

First-Line Platinum-Based Chemotherapy Re-challenge in Sensitive Small Cell Lung Cancer (SCLC): A Standard Treatment?

Giovenzio Genestreti, Monica Di Battista, Giovanna Cavallo and Alba Brandes

Small cell lung cancer (SCLC) has typically high sensitivity to chemotherapy and radiotherapy, although greater part of patients with limited disease (LD) and all patients with extended disease (ED) will develop disease relapse or progression, with an overall survival of 2-4 months in case of only best supportive care